創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
20/09/08 GEM215 Globo H-Specific CAR-T Cells Solid Tumor: breast cancer, gastric cancer and lung cancer i.v. Cell therapy Discovery Potential cell therapy for Globo H+ solid tumor.
-Combination with anti-PD-L1 Ab overcomes PD-L1-mediated immune suppression on CAR-T cells in tumor microenvironment.
-Anti PD-L1 Ab is able to induce bystander effect during Globo H CAR-T cell treatment.
問合せ
20/09/08 GEM214 Anti-K. pneumoniae (KP) Antibodies Multiple Drug Resistant (MDR) Klebsiella pneumoniae (KP) infection i.v. Antibody Preclinical GEM214 is an anti-MDR therapeutic antibody against Klebsiella pneumoniae Infection.
-A fully human mAb, has longer half-life and low immunogenicity.
-Antibody Antibiotics Conjugate (AAC) of GEM214 shows dose dependent intracellularly bactericidal potency.
問合せ
20/09/08 GEM213 Anti-CSF-1R antibody Cancer, PVNS (pigmented villonodular synovitis) i.v. Antibody Preclinical GEM213 is an antibody with high affinity and neutralizing ability.
- GEM213 can potently inhibit Colony Stimulating Factor Receptor 1 (CSF-1R) in cellular contexts and has the potential to induce a therapeutic effect on macrophages.
- GEM213 has unique CDR sequences and epitopes.
- GEM213 is a promising new agent with potential to combine with immune checkpoint inhibitors to relief macrophage-dependent immune suppression and would yield clinical benefit.
問合せ
20/09/03 GEM-CDV07 CK2 inhibitor COVID-19 Oral small molecule IND# - A promising therapeutic compound due to its dual impact on COVID-19
*Block stress granule disaggregation required for active viral replication
*Reduce cytokine storm
- GEM-CDV07 demonstrates potent anti-SARS-CoV-2 activity.
- In process of filing for emergency IND (eIND) to U.S. FDA to test ten patients.
#Phase 2 clinical trial is ongoing for other indication.
問合せ
20/08/26 GEM212 Antivirulent approach targeting antimicrobial resistance of Staphylococcus aureus infections S. aureus and MRSA Oral Small molecule Near completion of IND stage An antivirulent, non-bactericidal small molecule drug candidate for S. aureus infections, including MRSA, in a first-in-class oral form. Potentially reduces the risk of S. aureus resistance. A new mechanism to enhance the killing action of neutrophils. Phase II clinical trials are planned across multiple indications; bacteremia, pneumonia, endocarditis, bone and joint infections. 問合せ
20/08/26 GEM211 Antiviral Influenza A Oral Small molecule Lead optimization stage An antiviral with a more upstream target than Tamiflu, shown to be more effective in vivo. A small molecule, nucleozin, which targets viral nucleoprotein (NP), triggering the aggregation of NP and inhibiting
its nuclear accumulation. This impedes viral replication in vivo.
問合せ
20/08/26 GEM210 TFEB activation Alzheimer's and Parkinson's disease Oral Small molecule Lead optimization stage A new mechanism of action (and first-in-class oral form) to accelerate the degradation of neurotoxic proteins by autophagy. mTOR independent autophagy targets the removal of multiple misfolded proteins (e.g. beta-amyloid, tau) In several neurodegenerative diseases, mTOR/Transcriptional factor EB (TFEB) and therefore autophagy is dysfunctional. GEM210 increases TFEB translocation to the nucelus and enhances autophagy. 問合せ
20/08/26 GEM209 A3 adenosine receptor (A3AR) allosteric modulator Erectile dysfunction Oral Small molecule Preclinical ・Specific agonists of A3AR induce modulation of key signaling proteins, such as PI3K, GSK-3β, PKA, PKB/Akt, IKK, and NF-кB, and show anti-inflammatory effects.
・Very good safety profile.
・GEM209 increased eNOS and VEGF in the cavernosal endothelial cells.
・A single dose showed a full recovery in function of in an erectile dysfunction rat model.
問合せ
20/08/26 GEM208 A3 adenosine receptor (A3AR) agonist Liver cancer* NAFLD** Oral Small molecule Phase 3 in preparation* Phase 2 completed** ・A3AR is highly expressed in inflammatory and cancer cells. Specific agonists of A3AR induce apoptosis of cancer cells but not normal cells.
・Very good safety profile.
・An orphan drug status for hepatocellular carcinoma (HCC).
・In phase-2 study in HCC patients, it did not meet the primary endpoint (OS) but subgroup analysis of Child Pugh B patients showed a positive signal of efficacy for OS.
・In phase-2 study (vs placebo) in NAFLD/NASH, it met primary endpoint (liver enzyme) and reduced liver fat, fibrosis and steatosis.
問合せ
20/08/26 GEM207 A3 adenosine receptor (A3AR) agonist Rheumatoid arthritis (RA), Psoriasis Oral Small molecule Phase 3 ・A3AR is highly expressed in inflammatory and cancer cells. Specific agonists of A3AR induce apoptosis of inflammatory cells but not normal cells.
・Very good safety profile as 1st line therapy.
・In the pahse-2b study (monotherapy vs placebo) for12 weeks in naive RA patients, the endpoint was achieved.
・In the pahse-2/3 study (monotherapy vs placebo) in moderate to severe psoriasis patients, it did not meet the primary endpoint at 12 weeks, but at 32 week the improvement of PASI score was significant vs at 16 week.
・A phase-3 study (vs MTX) in moderate to severe RA and a phase-3 study (vs apremilast) are ongoing.
問合せ